Disintegration of sublingual tablets: proposal for a validated test method and acceptance criterion.
In the Netherlands the market share of isosorbide dinitrate 5 mg sublingual tablets is dominated by 2 products (A and B). In the last few years complaints have been received from health care professionals on product B. During patient use the disintegration of the tablet was reported to be slow and/or incomplete, and ineffectiveness was experienced. In the European Pharmacopoeia (Ph. Eur.) no requirement is present for the disintegration time of sublingual tablets. The purpose of this study was to compare the in vitro disintegration time of products A and B, and to establish a suitable test method and acceptance criterion. A and B were tested with the Ph. Eur. method described in the monograph on disintegration of tablets and capsules as well as with 3 modified tests using the same Ph. Eur. apparatus, but without movement of the basket-rack assembly. In modified test 1 and modified test 2 water was used as medium (900 ml and 50 ml respectively), whereas in modified test 3 artificial saliva was used (50 ml). In addition, disintegration was tested in Nessler tubes with 0.5 and 2 ml of water. Finally, the Ph. Eur. method was also applied to other sublingual tablets with other drug substances on the Dutch market. With modified test 3 no disintegration could be achieved within 20 min. With the Ph. Eur. method and modified tests 1 and 2 product A and B differed significantly (p < 0. 001), with product B having longer disintegration times. These 3 methods were capable of discriminating between products and between batches. The time measured with the Ph. Eur. method was significantly lower compared to modified tests 1 and 2 (p < 0.001) and correlated well with the Nessler tube results. It is concluded that the in vivo complaints on product B could be related to the in vitro data. Furthermore, it is proposed that for immediate release of sublingual tablets the disintegration time should be tested. The Ph. Eur. method is considered suitable for this test. In view of the products currently on the market and taking into consideration requirements in the United States Pharmacopeia and Japanese Pharmacopoeia, an acceptance criterion of not more than 2 min is proposed.
Weda
M
M
National Institute for Public Health and the Environment, Centre for Quality of Chemical-Pharmaceutical Products, Postbak 40, PO Box 1, 3720 BA Bilthoven, The Netherlands. marjolein.weda@rivm.nl
van Riet-Nales
D A
DA
van Aalst
P
P
de Kaste
D
D
Lekkerkerker
J F F
JF
D000286:Administration, Sublingual; D017408:Guidelines as Topic; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000737:chemistry*; D009426:Netherlands; D010602:Pharmacopoeias as Topic; D015203:Reproducibility of Results; D012463:Saliva / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000592:standards; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000737:chemistry*; D014867:Water / Q000737:chemistry
D013607:Tablets; D014665:Vasodilator Agents; D014867:Water; D007548:Isosorbide Dinitrate